Pharmaceuticals News and Research

RSS

Basil protects against harmful effects of ageing

Basil can protect against the harmful effects of ageing, according to research presented at the British Pharmaceutical Conference (BPC) in Manchester.

7 Sep 2008

Trial demonstrates safety and efficacy of neurally acting anti-migraine agent for treatment of acute migraine

CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced Phase II results of its lead compound COL-144 in the treatment of acute migraine. Results demonstrated that COL-144 was safe and effective in relieving migraine headaches.

7 Sep 2008

Coated lenses set to reduce 'post-op' infections for cataract patients

Research presented at the British Pharmaceutical Conference (BPC) in Manchester reveals that coating an artificial lens with antibiotics could significantly reduce the risk of post-operative infection, and even blindness, for cataract patients.

7 Sep 2008

Diabetics missing out on life saving medication

One in four patients with diabetes are not receiving the appropriate cardiovascular medications, research launched at the British Pharmaceutical Conference (BPC) in Manchester has shown.

7 Sep 2008

Patients at risk from unnecessary tubes

A third of patients have unnecessary tubes (cannulae) inserted when they are in hospital, needlessly exposing them to serious complications such as infection and blood clots, research launched at the British Pharmaceutical Conference (BPC) in Manchester has shown.

7 Sep 2008

Simple hardness test detects fake medicines

The fight against fake medicines could soon be aided by a small, portable device that quickly measures the hardness of a tablet, revealing whether it is counterfeit, according to research presented at the British Pharmaceutical Conference (BPC) in Manchester.

7 Sep 2008

Light-activated drug used to tackle MRSA

New treatment using a light-activated drug could revolutionise the fight against hospital "superbug", MRSA (otherwise known as Meticillin resistant staphylococcus aureus) it was revealed at the British Pharmaceutical Conference (BPC) in Manchester.

7 Sep 2008

Myalgic encephalomyelitis sufferers rely on aternative medicines

More than a third of patients with long-term fatigue conditions like Myalgic Encephalomyelitis (ME) believe complementary and alternative medicines (CAMs) are more effective than traditional medicine in treating their illness, research launched at the British Pharmaceutical Conference (BPC) in Manchester reveals.

7 Sep 2008

Free drug samples may end up costing uninsured more

Free drug samples provided to physicians by pharmaceutical companies could actually be costing uninsured patients more in the long run, according to a study done by researchers at Wake Forest University Baptist Medical Center and colleagues.

7 Sep 2008

Gilead's antiretroviral patent request rejected by Brazil

A patent request from the pharmaceutical company Gilead for its antiretroviral drug tenofovir was rejected by Brazil Wednesday, Reuters reports.

4 Sep 2008

Nanotherapeutics files INDA for NanoDOX hydrogel to treat type of diabetic ulcers

Nanotherapeutics announced today that it has submitted its first Investigational New Drug (IND) application to the FDA for a phase IIa clinical study for its product NanoDOX Hydrogel, a topical doxycycline hydrogel for chronic wounds.

4 Sep 2008

FDA assigns priority review to ATryn from GTC Biotherapeutics

The US Food and Drug Administration, or FDA, has assigned Priority Review to GTC Biotherapeutics, Inc.'s Biologic License Application, or BLA, for ATryn.

4 Sep 2008

Celgene receives FDA 'fast track' for Amrubicin in small cell lung cancer after first-line chemotherapy

Celgene Corporation today announced that Amrubicin has been granted Fast Track product designation by the U.S. Food and Drug Administration (FDA) for the treatment of small cell lung cancer after first-line chemotherapy.

4 Sep 2008

Second phase 3 trial of Bronchitol in cystic fibrosis sufferers begins

Pharmaceutical company Pharmaxis today announced that it has enrolled the first subject into its second pivotal Phase 3 clinical trial evaluating Bronchitol in cystic fibrosis sufferers.

4 Sep 2008

Panacea Pharmaceuticals issued U.S. patent for anti-HAAH antibodies

Panacea Pharmaceuticals, Inc. has announced the issuance of U.S. Patent Number 7,413,737 covering antibodies against human aspartyl (asparaginyl) beta-hydroxylase (HAAH), a proprietary human cancer biomarker and therapeutic target.

3 Sep 2008

Diffusion Pharmaceuticals initiates phase I/II clinical trial in patients with peripheral arterial disease

Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing new drugs for the treatment of unmet medical needs, announced today that it has begun to enroll patients in a Phase I/II clinical trial of its lead drug candidate trans sodium crocetinate (TSC).

3 Sep 2008

Alte Biosciences files patent for novel inflammatory bowel disease drugs

Alte Bioscience, Inc., a development stage pharmaceutical company, is pleased to announce the filing of a provisional patent for a new class of drugs that may benefit patients with inflammatory bowel disease.

3 Sep 2008

Anadis Ltd's clinical trial against mucositis approved in Israel

Anadis Ltd., an Australian biopharmaceutical company specializing in oral immunotherapy using naturally derived antibodies and other proteins is announcing the clinical protocol for its Cancer-related Mucositis Program was cleared by the Tel Aviv Souraski Medical Center's Institutional Review Board (IRB) and by the Israeli Ministry of Health (MOH).

3 Sep 2008

Spinifex secures major investment to develop pain drug

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced it has secured venture capital investment of A$12 million from GBS Venture Partners Limited, Brandon Capital Partners and Uniseed to fund the development of its pain management drug, EMA401.

2 Sep 2008

Nature inspires new highly specific drugs and organic products

The best place to seek novel compounds for pharmaceutical drugs, alternative energy sources, and a host of industrial applications, is within natural systems that have evolved over millions of years.

2 Sep 2008